The PE Data Center Buzz
Posted by PEDC Analysis Team
August 28, 2008
This week we are going to take a look at a few biotechnology companies since this industry continues to be one of the top investment focuses of many VC firms. There were several biotech deals in Q2 2008 that brought in more than $20 MM each. The VC Experts analyst team has reviewed a few of the top Biotech deals from Q2 2008, and the full report of the valuations and deal terms can be seen at the Private Equity Data Center blog.
Cost of Capital Benchmark
We analyzed deals from Gloucester Pharmaceuticals, Inc., Kythera Biopharmaceuticals, Inc. (formerly Aestherx, Inc), and Stromedix Inc. After reviewing the deals, we input the findings of the deal term information into our "Cost of Capital Benchmark". You can see that Gloucester, Inc. and Kythera Biopharmaceuticals, Inc. came in with slightly better "company friendly" capital.
Keep in mind, the lower you are on the chart, the more company-friendly the money, the higher you go on the chart, the more investor-friendly the money. If you are a company raising money, you want be lower on the chart. This is a time when it is not best to be on top if you are the company raising money.
Permalink |
Send to Colleague |
Comments |
